Atea Pharmaceuticals (AVIR)

• Market cap: $248M
• 1 day: 0.34%
• 5 days: -13.53%
• 1 month: -17.88%
• 3 months: -18.33%
• 6 months: -22.63%
• Year to date: -8.41%
• 1 year: -1.34%
• 5 years: -90.31%
• 10 years: -90.31%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).

Employees: 75

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

30% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 30

25% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 12

3% more funds holding

Funds holding: 104 [Q2] → 107 (+3) [Q3]

3% more capital invested

Capital invested by funds: $189M [Q2] → $194M (+$5.04M) [Q3]

0.85% more ownership

Funds ownership: 67.75% [Q2] → 68.59% (+0.85%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

96% less call options, than puts

Call options by funds: $88K | Put options by funds: $2.31M